Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Researchers at Fred Hutch Cancer Center have discovered an overlooked mechanism driving aggressive breast and brain tumors ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

With cancer rising in women under 40, there's concern about the causes — and the effects. PEOPLE's editor-in-chief Charlotte ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...

Award-winning research presented at ESR 2025 reveals energy-efficient diagnostic approaches for metastatic breast cancer, ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4 ...

Mark Erlander; Chief Executive Officer, Director; Cardiff Oncology Inc. James Levine; Chief Financial Officer; Cardi ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...